NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.

Novocure, a global oncology company, announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the country’s National Health Insurance coverage.

BAAR, Switzerland - Novocure (NASDAQ:NVCR) announced Monday that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the country’s National Health Insurance ...

Through non-invasive, wearable arrays, Optune Lua uses TTFields to exert physical forces on the electrically charged components of the dividing cancer cells. [Image courtesy of Novocure] Novocure ...

Noninvasive TTFields (Optune Pax) gained approval with gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer, introducing a device-based modality in a ...

The Food and Drug Administration has signed off on Optune Pax, a wearable device that uses alternating electrical fields to treat adults with locally advanced, inoperable pancreatic cancer. The ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...